BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waldner MJ, Neurath MF. Targeting the VEGF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012;16:5-13. [DOI: 10.1517/14728222.2011.641951] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Georgiadou D, Sergentanis T, Sakellariou S, Filippakis G, Zagouri F, Vlachodimitropoulos D, Psaltopoulou T, Lazaris A, Patsouris E, Zografos G. VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis. European Journal of Surgical Oncology (EJSO) 2014;40:1331-7. [DOI: 10.1016/j.ejso.2014.01.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
2 Zou J, Liu Y, Wang J, Liu Z, Lu Z, Chen Z, Li Z, Dong B, Huang W, Li Y, Gao J, Shen L. Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. J Transl Med 2018;16:15. [PMID: 29370817 DOI: 10.1186/s12967-018-1379-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang S, Li Z, Hu G. Prognostic role of intratumoral IL-17A expression by immunohistochemistry in solid tumors: a meta-analysis. Oncotarget 2017;8:66382-91. [PMID: 29029520 DOI: 10.18632/oncotarget.18807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
4 Prabhakaran J, Arango V, Majo VJ, Simpson NR, Kassir SA, Underwood MD, Polavarapu H, Bruce JN, Canoll P, Mann JJ, Kumar JS. Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2. Bioorg Med Chem Lett 2012;22:5104-7. [PMID: 22749281 DOI: 10.1016/j.bmcl.2012.05.099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
5 Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer 2015;62:45-51. [PMID: 25257751 DOI: 10.1002/pbc.25229] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
6 Guaiquil VH, Pan Z, Karagianni N, Fukuoka S, Alegre G, Rosenblatt MI. VEGF-B selectively regenerates injured peripheral neurons and restores sensory and trophic functions. Proc Natl Acad Sci U S A 2014;111:17272-7. [PMID: 25404333 DOI: 10.1073/pnas.1407227111] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
7 Tlemsani C, Mir O, Psimaras D, Vano YA, Ducreux M, Escudier B, Rousseau B, Loirat D, Ceccaldi B, André T, Goldwasser F, Ricard D. Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. Eur J Cancer 2016;66:75-82. [PMID: 27529757 DOI: 10.1016/j.ejca.2016.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Hondermarck H. Neurotrophins and their receptors in breast cancer. Cytokine & Growth Factor Reviews 2012;23:357-65. [DOI: 10.1016/j.cytogfr.2012.06.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
9 Diab NS, Barish S, Dong W, Zhao S, Allington G, Yu X, Kahle KT, Brueckner M, Jin SC. Molecular Genetics and Complex Inheritance of Congenital Heart Disease. Genes (Basel) 2021;12:1020. [PMID: 34209044 DOI: 10.3390/genes12071020] [Reference Citation Analysis]
10 Al-Wadei HA, Al-Wadei MH, Ullah MF, Schuller HM. Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS One 2012;7:e43376. [PMID: 22916251 DOI: 10.1371/journal.pone.0043376] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
11 Zhu P, Hu C, Hui K, Jiang X. The role and significance of VEGFR2+ regulatory T cells in tumor immunity. Onco Targets Ther 2017;10:4315-9. [PMID: 28919780 DOI: 10.2147/OTT.S142085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
12 Das M, Law S. Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. The International Journal of Biochemistry & Cell Biology 2018;103:115-24. [DOI: 10.1016/j.biocel.2018.08.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
13 Jones VS, Huang R, Chen L, Chen Z, Fu L, Huang R. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2016;1865:255-65. [DOI: 10.1016/j.bbcan.2016.03.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 76] [Article Influence: 7.8] [Reference Citation Analysis]
14 Xu X, Yan Y, Xun Q, Shi J, Kong X, Wu J, Zhou H. Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line. Onco Targets Ther 2019;12:1215-23. [PMID: 30863089 DOI: 10.2147/OTT.S194064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Laschke MW, Vorsterman van Oijen AE, Körbel C, Scheuer C, Menger MD. 4-Hydroxybenzyl alcohol: A novel inhibitor of tumor angiogenesis and growth. Life Sciences 2013;93:44-50. [DOI: 10.1016/j.lfs.2013.05.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
16 Liu Y, Suzuki M, Masunaga S, Chen YW, Kashino G, Tanaka H, Sakurai Y, Kirihata M, Ono K. Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor. J Radiat Res 2013;54:260-7. [PMID: 23135099 DOI: 10.1093/jrr/rrs102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Zhang X, Tang W, Chen G, Ren F, Liang H, Dang Y, Rong M. An Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding Overlaps. PLoS One 2016;11:e0159498. [PMID: 27467251 DOI: 10.1371/journal.pone.0159498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
18 Shahbazian D, Sznol J, Kluger HM. Vertical Pathway Targeting in Cancer Therapy. Current Challenges in Personalized Cancer Medicine. Elsevier; 2012. pp. 1-26. [DOI: 10.1016/b978-0-12-397927-8.00001-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
19 Kameswaran M, Pandey U, Gamre N, Vimalnath KV, Sarma HD, Dash A. Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers. Appl Radiat Isot 2016;114:196-201. [PMID: 27258216 DOI: 10.1016/j.apradiso.2016.05.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Shah F, Logsdon D, Messmann RA, Fehrenbacher JC, Fishel ML, Kelley MR. Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol 2017;1:19. [PMID: 28825044 DOI: 10.1038/s41698-017-0023-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
21 Wang R, Han Y, Zhao Z, Yang F, Chen T, Zhou W, Wang X, Qi L, Zhao W, Guo Z, Gu Y. Link synthetic lethality to drug sensitivity of cancer cells. Brief Bioinform 2019;20:1295-307. [PMID: 29300844 DOI: 10.1093/bib/bbx172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Vásquez AF, González Barrios AF. Classical MD and metadynamics simulations on back-pocket binders of CDK2 and VEGFR2: a guidepost to design novel small-molecule dual inhibitors. J Biomol Struct Dyn 2021;:1-12. [PMID: 33949282 DOI: 10.1080/07391102.2021.1922311] [Reference Citation Analysis]
23 Fleetwood F, Güler R, Gordon E, Ståhl S, Claesson-welsh L, Löfblom J. Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling. Cell Mol Life Sci 2016;73:1671-83. [DOI: 10.1007/s00018-015-2088-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
24 Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM. Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res 2016;6:4. [PMID: 26780081 DOI: 10.1186/s13550-016-0163-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Zhang YL, Ma Y, Zeng YQ, Liu Y, He EP, Liu YT, Qiao FL, Yu R, Wang YS, Wu XY, Leng P. A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics. Ann Transl Med 2021;9:1704. [PMID: 34988213 DOI: 10.21037/atm-21-5271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhao S, Wu D, Wu P, Wang Z, Huang J. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis. PLoS One. 2015;10:e0139598. [PMID: 26440936 DOI: 10.1371/journal.pone.0139598] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 7.3] [Reference Citation Analysis]
27 Torijano-gutiérrez S, Díaz-oltra S, Falomir E, Murga J, Carda M, Marco JA. Synthesis of combretastatin A-4 O-alkyl derivatives and evaluation of their cytotoxic, antiangiogenic and antitelomerase activity. Bioorganic & Medicinal Chemistry 2013;21:7267-74. [DOI: 10.1016/j.bmc.2013.09.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhang Z, Zhang H, Peng T, Li D, Xu J. Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma. Oncol Lett 2016;11:610-8. [PMID: 26870255 DOI: 10.3892/ol.2015.3957] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
29 Zhu H, Jiang X, Zhou X, Dong X, Xie K, Yang C, Jiang H, Sun X, Lu J. Neuropilin-1 regulated by miR-320 contributes to the growth and metastasis of cholangiocarcinoma cells. Liver Int. 2018;38:125-135. [PMID: 28618167 DOI: 10.1111/liv.13495] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
30 Boyineni J, Tanpure S, Gnanamony M, Antony R, Fernández KS, Lin J, Pinson D, Gondi CS. SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR‑410 in human neuroblastoma cells. Int J Oncol 2016;49:1394-406. [PMID: 27498840 DOI: 10.3892/ijo.2016.3646] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
31 Park JM, Kim YJ, Song MK, Lee JM, Kim YJ. Genome‑wide DNA methylation profiling in a rat model with vascular dementia. Mol Med Rep 2018;18:123-30. [PMID: 29749552 DOI: 10.3892/mmr.2018.8990] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Zhang W, Zeng T, Liu X, Chen L. Diagnosing phenotypes of single-sample individuals by edge biomarkers. J Mol Cell Biol 2015;7:231-41. [DOI: 10.1093/jmcb/mjv025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
33 Torok S, Vegvari A, Rezeli M, Fehniger TE, Tovari J, Paku S, Laszlo V, Hegedus B, Rozsas A, Dome B, Marko-Varga G. Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study. Br J Pharmacol 2015;172:1148-63. [PMID: 25363319 DOI: 10.1111/bph.12990] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
34 Lorusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs 2014;32:303-11. [DOI: 10.1007/s10637-013-9998-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
35 Zhang X, Ye ZH, Liang HW, Ren FH, Li P, Dang YW, Chen G. Down-regulation of miR-146a-5p and its potential targets in hepatocellular carcinoma validated by a TCGA- and GEO-based study. FEBS Open Bio 2017;7:504-21. [PMID: 28396836 DOI: 10.1002/2211-5463.12198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
36 Zhang Q, Li H, Jin H, Tan H, Zhang J, Sheng S. The global landscape of intron retentions in lung adenocarcinoma. BMC Med Genomics 2014;7:15. [PMID: 24646369 DOI: 10.1186/1755-8794-7-15] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
37 Wang Y, Hu B, Peng Y, Xiong X, Jing W, Wang J, Gao H. In Silico Exploration of the Molecular Mechanism of Cassane Diterpenoids on Anti-inflammatory and Immunomodulatory Activity. J Chem Inf Model 2019;59:2309-23. [DOI: 10.1021/acs.jcim.8b00862] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
38 Youngblood V, Wang S, Song W, Walter D, Hwang Y, Chen J, Brantley-Sieders DM. Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium. Mol Cancer Res 2015;13:524-37. [PMID: 25504371 DOI: 10.1158/1541-7786.MCR-14-0142] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
39 Mahdi A, Darvishi B, Majidzadeh-A K, Salehi M, Farahmand L. Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies. J Cell Physiol 2019;234:5655-63. [PMID: 30515806 DOI: 10.1002/jcp.27414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
40 Martí-centelles R, Cejudo-marín R, Falomir E, Murga J, Carda M, Alberto Marco J. Inhibition of VEGF expression in cancer cells and endothelial cell differentiation by synthetic stilbene derivatives. Bioorganic & Medicinal Chemistry 2013;21:3010-5. [DOI: 10.1016/j.bmc.2013.03.072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
41 Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group. Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study. Neoplasia 2017;19:93-9. [PMID: 28088688 DOI: 10.1016/j.neo.2016.08.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
42 Wu D, Shi Z, Xu H, Chen R, Xue S, Sun X. Knockdown of Cripto-1 inhibits the proliferation, migration, invasion, and angiogenesis in prostate carcinoma cells. J Biosci 2017;42:405-16. [PMID: 29358554 DOI: 10.1007/s12038-017-9700-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
43 Li GJ, Yang Y, Yang GK, Wan J, Cui DL, Ma ZH, Du LJ, Zhang GM. Slit2 suppresses endothelial cell proliferation and migration by inhibiting the VEGF-Notch signaling pathway. Mol Med Rep 2017;15:1981-8. [PMID: 28260032 DOI: 10.3892/mmr.2017.6240] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
44 Piazuelo MB, Riechelmann RP, Wilson KT, Algood HMS. Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy. Curr Top Microbiol Immunol 2019;421:319-59. [PMID: 31123895 DOI: 10.1007/978-3-030-15138-6_13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
45 Everett RA, Nagy JD, Kuang Y. Dynamics of a Data Based Ovarian Cancer Growth and Treatment Model with Time Delay. J Dyn Diff Equat 2016;28:1393-414. [DOI: 10.1007/s10884-015-9498-y] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Li M, Dai N, Wang D, Zhong Z. Distinct APE1 Activities Affect the Regulation of VEGF Transcription Under Hypoxic Conditions. Comput Struct Biotechnol J 2019;17:324-32. [PMID: 30906512 DOI: 10.1016/j.csbj.2019.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]